Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Ingenovis Health comprehensive restructuring transactions
We advised Ingenovis Health in connection with the restructuring
Editas Medicine $125 million follow-on offering
We advised the joint book-running managers on the offering
Merck $6 billion notes offering
We advised the underwriters on the offering
Immix Biopharma $150 million stock offering
We advised the lead bookrunner and the underwriters on the offering
Oruka Therapeutics collaboration with Halozyme
We advised Oruka Therapeutics on the transaction
Purdue Pharma completes chapter 11 restructuring
We advised Purdue in connection with its nearly seven year-long chapter 11 restructuring
GH Research $200 million at-the-market offering
We advised GH Research on the establishment of the at-the-market program
METiS TechBio HK$2.43 billion IPO
We advised METiS TechBio on its IPO and HKEX listing
Tempus AI $460 million convertible senior notes offering
We advised the representatives of the several initial purchasers on the offering
Personalis $150 million at-the-market offering
We advised the sales agents on the offering